Stocktwits users spotted a media report about Richard Magides, the director of Singapore-based Zentree Investment and 23andMe's second-largest shareholder, expressing interest in backing a rescue effort....
Short interest in the stock has grown steadily since mid-December, rising from 0.9% to 8.5% by the end of January, according to Koyfin data.
Chairman Jonathan Javitt said the resources committed are expected to bring NRx to the $100 million revenue threshold.
The latest approval adds to BeiGene’s momentum, marking six EU indications granted in just over a year.